

**SENATE  
STATE OF MINNESOTA  
NINETIETH SESSION**

**S.F. No. 2578**

(SENATE AUTHORS: ANDERSON, P., Limmer, Johnson and Draheim)

DATE  
02/22/2018

D-PG

Introduction and first reading  
Referred to Judiciary and Public Safety Finance and Policy

OFFICIAL STATUS

1.1 A bill for an act  
1.2 relating to public safety; modifying the schedules of controlled substances;  
1.3 amending Minnesota Statutes 2016, section 152.02, subdivision 5; Minnesota  
1.4 Statutes 2017 Supplement, section 152.02, subdivision 2.

1.5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 Section 1. Minnesota Statutes 2017 Supplement, section 152.02, subdivision 2, is amended  
1.7 to read:

1.8 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.

1.9 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the  
1.10 following substances, including their analogs, isomers, esters, ethers, salts, and salts of  
1.11 isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,  
1.12 and salts is possible:

1.13 (1) acetylmethadol;

1.14 (2) allylprodine;

1.15 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl  
1.16 acetate);

1.17 (4) alphameprodine;

1.18 (5) alphamethadol;

1.19 (6) alpha-methylfentanyl benzethidine;

1.20 (7) betacetylmethadol;

1.21 (8) betameprodine;

- 2.1 (9) betamethadol;
- 2.2 (10) betaprodine;
- 2.3 (11) clonitazene;
- 2.4 (12) dextromoramide;
- 2.5 (13) diampromide;
- 2.6 (14) diethylambutene;
- 2.7 (15) difenoxin;
- 2.8 (16) dimenoxadol;
- 2.9 (17) dimepheptanol;
- 2.10 (18) dimethylambutene;
- 2.11 (19) dioxaphetyl butyrate;
- 2.12 (20) dipipanone;
- 2.13 (21) ethylmethylthiambutene;
- 2.14 (22) etonitazene;
- 2.15 (23) etoxeridine;
- 2.16 (24) furethidine;
- 2.17 (25) hydroxypethidine;
- 2.18 (26) ketobemidone;
- 2.19 (27) levomoramide;
- 2.20 (28) levophenacilmorphan;
- 2.21 (29) 3-methylfentanyl;
- 2.22 (30) acetyl-alpha-methylfentanyl;
- 2.23 (31) alpha-methylthiofentanyl;
- 2.24 (32) benzylfentanyl beta-hydroxyfentanyl;
- 2.25 (33) beta-hydroxy-3-methylfentanyl;
- 2.26 (34) 3-methylthiofentanyl;
- 2.27 (35) thenylfentanyl;

- 3.1 (36) thiofentanyl;
- 3.2 (37) para-fluorofentanyl;
- 3.3 (38) morpheridine;
- 3.4 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 3.5 (40) noracymethadol;
- 3.6 (41) norlevorphanol;
- 3.7 (42) normethadone;
- 3.8 (43) norpipanone;
- 3.9 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 3.10 (45) phenadoxone;
- 3.11 (46) phenampromide;
- 3.12 (47) phenomorphan;
- 3.13 (48) phenoperidine;
- 3.14 (49) piritramide;
- 3.15 (50) proheptazine;
- 3.16 (51) properidine;
- 3.17 (52) propiram;
- 3.18 (53) racemoramide;
- 3.19 (54) tilidine;
- 3.20 (55) trimeperidine;
- 3.21 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
- 3.22 (57)
- 3.23 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide(U47700);
- 3.24 ~~and~~
- 3.25 (58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);
- 3.26 (59) mitragynine;
- 3.27 (60) 7-hydroxymitragynine; and
- 3.28 (61) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol).

4.1 (c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,  
4.2 and salts of isomers, unless specifically excepted or unless listed in another schedule,  
4.3 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

4.4 (1) acetorphine;

4.5 (2) acetyldihydrocodeine;

4.6 (3) benzylmorphine;

4.7 (4) codeine methylbromide;

4.8 (5) codeine-n-oxide;

4.9 (6) cyprenorphine;

4.10 (7) desomorphine;

4.11 (8) dihydromorphine;

4.12 (9) drotebanol;

4.13 (10) etorphine;

4.14 (11) heroin;

4.15 (12) hydromorphanol;

4.16 (13) methyl-desorphine;

4.17 (14) methyldihydromorphine;

4.18 (15) morphine methylbromide;

4.19 (16) morphine methylsulfonate;

4.20 (17) morphine-n-oxide;

4.21 (18) myrophine;

4.22 (19) nicocodeine;

4.23 (20) nicomorphine;

4.24 (21) normorphine;

4.25 (22) pholcodine; and

4.26 (23) thebacon.

4.27 (d) Hallucinogens. Any material, compound, mixture or preparation which contains any  
4.28 quantity of the following substances, their analogs, salts, isomers (whether optical, positional,

5.1 or geometric), and salts of isomers, unless specifically excepted or unless listed in another  
5.2 schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is  
5.3 possible:

- 5.4 (1) methylenedioxy amphetamine;
- 5.5 (2) methylenedioxymethamphetamine;
- 5.6 (3) methylenedioxy-N-ethylamphetamine (MDEA);
- 5.7 (4) n-hydroxy-methylenedioxyamphetamine;
- 5.8 (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
- 5.9 (6) 2,5-dimethoxyamphetamine (2,5-DMA);
- 5.10 (7) 4-methoxyamphetamine;
- 5.11 (8) 5-methoxy-3, 4-methylenedioxyamphetamine;
- 5.12 (9) alpha-ethyltryptamine;
- 5.13 (10) bufotenine;
- 5.14 (11) diethyltryptamine;
- 5.15 (12) dimethyltryptamine;
- 5.16 (13) 3,4,5-trimethoxyamphetamine;
- 5.17 (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
- 5.18 (15) ibogaine;
- 5.19 (16) lysergic acid diethylamide (LSD);
- 5.20 (17) mescaline;
- 5.21 (18) parahexyl;
- 5.22 (19) N-ethyl-3-piperidyl benzilate;
- 5.23 (20) N-methyl-3-piperidyl benzilate;
- 5.24 (21) psilocybin;
- 5.25 (22) psilocyn;
- 5.26 (23) tenocyclidine (TPCP or TCP);
- 5.27 (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
- 5.28 (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);

- 6.1 (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
- 6.2 (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
- 6.3 (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
- 6.4 (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
- 6.5 (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
- 6.6 (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
- 6.7 (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
- 6.8 (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
- 6.9 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
- 6.10 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
- 6.11 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
- 6.12 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
- 6.13 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
- 6.14 (2-CB-FLY);
- 6.15 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
- 6.16 (40) alpha-methyltryptamine (AMT);
- 6.17 (41) N,N-diisopropyltryptamine (DiPT);
- 6.18 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
- 6.19 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
- 6.20 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
- 6.21 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
- 6.22 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
- 6.23 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
- 6.24 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
- 6.25 (49) 5-methoxy- $\alpha$ -methyltryptamine (5-MeO-AMT);
- 6.26 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 6.27 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);

- 7.1 (52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
- 7.2 (53) 5-methoxy- $\alpha$ -ethyltryptamine (5-MeO-AET);
- 7.3 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
- 7.4 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
- 7.5 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
- 7.6 (57) methoxetamine (MXE);
- 7.7 (58) 5-iodo-2-aminoindane (5-IAI);
- 7.8 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
- 7.9 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
- 7.10 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
- 7.11 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
- 7.12 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 7.13 (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
- 7.14 (65) N,N-Dipropyltryptamine (DPT);
- 7.15 (66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
- 7.16 (67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
- 7.17 (68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
- 7.18 (69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
- 7.19 (70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylorketamine,  
7.20 ethketamine, NENK);
- 7.21 (71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
- 7.22 (72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
- 7.23 (73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).

7.24 (e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii*  
7.25 Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,  
7.26 and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,  
7.27 its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not  
7.28 apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian  
7.29 Church, and members of the American Indian Church are exempt from registration. Any

8.1 person who manufactures peyote for or distributes peyote to the American Indian Church,  
8.2 however, is required to obtain federal registration annually and to comply with all other  
8.3 requirements of law.

8.4 (f) Central nervous system depressants. Unless specifically excepted or unless listed in  
8.5 another schedule, any material compound, mixture, or preparation which contains any  
8.6 quantity of the following substances, their analogs, salts, isomers, and salts of isomers  
8.7 whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

8.8 (1) mecloqualone;

8.9 (2) methaqualone;

8.10 (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;

8.11 (4) flunitrazepam; and

8.12 (5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine,  
8.13 methoxyketamine).

8.14 (g) Stimulants. Unless specifically excepted or unless listed in another schedule, any  
8.15 material compound, mixture, or preparation which contains any quantity of the following  
8.16 substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the  
8.17 analogs, salts, isomers, and salts of isomers is possible:

8.18 (1) aminorex;

8.19 (2) cathinone;

8.20 (3) fenethylamine;

8.21 (4) methcathinone;

8.22 (5) methylaminorex;

8.23 (6) N,N-dimethylamphetamine;

8.24 (7) N-benzylpiperazine (BZP);

8.25 (8) methylmethcathinone (mephedrone);

8.26 (9) 3,4-methylenedioxy-N-methylcathinone (methydone);

8.27 (10) methoxymethcathinone (methedrone);

8.28 (11) methylenedioxypropylone (MDPV);

8.29 (12) 3-fluoro-N-methylcathinone (3-FMC);



- 9.1 (13) methylethcathinone (MEC);
- 9.2 (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
- 9.3 (15) dimethylmethcathinone (DMMC);
- 9.4 (16) fluoroamphetamine;
- 9.5 (17) fluoromethamphetamine;
- 9.6 (18)  $\alpha$ -methylaminobutyrophenone (MABP or buphedrone);
- 9.7 (19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
- 9.8 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
- 9.9 (21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
- 9.10 naphyrone);
- 9.11 (22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
- 9.12 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
- 9.13 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
- 9.14 (25) 4-methyl-N-ethylcathinone (4-MEC);
- 9.15 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
- 9.16 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
- 9.17 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
- 9.18 (29) 4-fluoro-N-methylcathinone (4-FMC);
- 9.19 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
- 9.20 (31) alpha-pyrrolidinobutiophenone ( $\alpha$ -PBP);
- 9.21 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
- 9.22 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
- 9.23 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
- 9.24 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
- 9.25 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
- 9.26 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
- 9.27 ~~and~~
- 9.28 (38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP); and

10.1 ~~(38)~~ (39) any other substance, except bupropion or compounds listed under a different  
10.2 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the  
10.3 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the  
10.4 compound is further modified in any of the following ways:

10.5 (i) by substitution in the ring system to any extent with alkyl, alkylendioxy, alkoxy,  
10.6 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring  
10.7 system by one or more other univalent substituents;

10.8 (ii) by substitution at the 3-position with an acyclic alkyl substituent;

10.9 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or  
10.10 methoxybenzyl groups; or

10.11 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.

10.12 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically  
10.13 excepted or unless listed in another schedule, any natural or synthetic material, compound,  
10.14 mixture, or preparation that contains any quantity of the following substances, their analogs,  
10.15 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence  
10.16 of the isomers, esters, ethers, or salts is possible:

10.17 (1) marijuana;

10.18 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic  
10.19 equivalents of the substances contained in the cannabis plant or in the resinous extractives  
10.20 of the plant, or synthetic substances with similar chemical structure and pharmacological  
10.21 activity to those substances contained in the plant or resinous extract, including, but not  
10.22 limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4  
10.23 cis or trans tetrahydrocannabinol;

10.24 (3) synthetic cannabinoids, including the following substances:

10.25 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole  
10.26 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,  
10.27 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or  
10.28 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any  
10.29 extent and whether or not substituted in the naphthyl ring to any extent. Examples of  
10.30 naphthoylindoles include, but are not limited to:

10.31 (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

10.32 (B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

- 11.1 (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
- 11.2 (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
- 11.3 (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
- 11.4 (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
- 11.5 (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
- 11.6 (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
- 11.7 (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
- 11.8 (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
- 11.9 (ii) Naphthylmethyloindoles, which are any compounds containing a
- 11.10 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the
- 11.11 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 11.12 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
- 11.13 substituted in the indole ring to any extent and whether or not substituted in the naphthyl
- 11.14 ring to any extent. Examples of naphthylmethyloindoles include, but are not limited to:
- 11.15 (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
- 11.16 (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
- 11.17 (iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole
- 11.18 structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
- 11.19 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 11.20 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any
- 11.21 extent, whether or not substituted in the naphthyl ring to any extent. Examples of
- 11.22 naphthoylpyrroles include, but are not limited to,
- 11.23 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
- 11.24 (iv) Naphthylmethyloindenes, which are any compounds containing a naphthylideneindene
- 11.25 structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,
- 11.26 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 11.27 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any
- 11.28 extent, whether or not substituted in the naphthyl ring to any extent. Examples of
- 11.29 naphthylmethyloindenes include, but are not limited to,
- 11.30 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
- 11.31 (v) Phenylacetyloindoles, which are any compounds containing a 3-phenylacetyloindole
- 11.32 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,

- 12.1 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or  
12.2 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any  
12.3 extent, whether or not substituted in the phenyl ring to any extent. Examples of  
12.4 phenylacetylindoles include, but are not limited to:
- 12.5 (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);  
12.6 (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);  
12.7 (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);  
12.8 (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
- 12.9 (vi) Cyclohexylphenols, which are compounds containing a  
12.10 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic  
12.11 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
12.12 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted  
12.13 in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not  
12.14 limited to:
- 12.15 (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);  
12.16 (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol  
12.17 (Cannabicyclohexanol or CP 47,497 C8 homologue);  
12.18 (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]  
12.19 -phenol (CP 55,940).
- 12.20 (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure  
12.21 with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,  
12.22 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or  
12.23 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any  
12.24 extent and whether or not substituted in the phenyl ring to any extent. Examples of  
12.25 benzoylindoles include, but are not limited to:
- 12.26 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);  
12.27 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);  
12.28 (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN  
12.29 48,098 or Pravadoline).
- 12.30 (viii) Others specifically named:

- 13.1 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)  
13.2 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
- 13.3 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)  
13.4 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
- 13.5 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]  
13.6 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
- 13.7 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
- 13.8 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone  
13.9 (XLR-11);
- 13.10 (F) 1-pentyl-N-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-1H-indazole-3-carboxamide  
13.11 (AKB-48(APINACA));
- 13.12 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide  
13.13 (5-Fluoro-AKB-48);
- 13.14 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
- 13.15 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
- 13.16 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide  
13.17 (AB-PINACA);
- 13.18 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-  
13.19 1H-indazole-3-carboxamide (AB-FUBINACA);
- 13.20 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-  
13.21 indazole-3-carboxamide(AB-CHMINACA);
- 13.22 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate  
13.23 (5-fluoro-AMB);
- 13.24 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
- 13.25 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone  
13.26 (FUBIMINA);
- 13.27 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo  
13.28 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
- 13.29 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)  
13.30 -1H-indole-3-carboxamide (5-fluoro-ABICA);

- 14.1 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)  
 14.2 -1H-indole-3-carboxamide;
- 14.3 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)  
 14.4 -1H-indazole-3-carboxamide;
- 14.5 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;
- 14.6 (U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1  
 14.7 H-indazole-3-carboxamide (MAB-CHMINACA);
- 14.8 (V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide  
 14.9 (ADB-PINACA);
- 14.10 (W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
- 14.11 (X)  
 14.12 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide.  
 14.13 (APP-CHMINACA);
- 14.14 (Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
- 14.15 (Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
- 14.16 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended  
 14.17 for human consumption.
- 14.18 Sec. 2. Minnesota Statutes 2016, section 152.02, subdivision 5, is amended to read:
- 14.19 Subd. 5. **Schedule IV.** (a) Schedule IV consists of the substances listed in this subdivision.
- 14.20 (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,  
 14.21 any material, compound, mixture, or preparation containing any of the following narcotic  
 14.22 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities  
 14.23 as follows:
- 14.24 (1) not more than one milligram of difenoxin and not less than 25 micrograms of atropine  
 14.25 sulfate per dosage unit;
- 14.26 (2) dextropropoxyphene (Darvon and Darvocet);
- 14.27 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and  
 14.28 geometric isomers, and salts of these isomers (including tramadol); ~~and~~
- 14.29 (4) eluxadoline;<sub>2</sub>
- 14.30 (5) pentazocine; and

15.1 (6) butorphanol (including its optical isomers).

15.2 (c) Depressants. Unless specifically excepted or unless listed in another schedule, any  
15.3 material, compound, mixture, or preparation containing any quantity of the following  
15.4 substances, including its salts, isomers, and salts of isomers whenever the existence of the  
15.5 salts, isomers, and salts of isomers is possible:

15.6 (1) alfaxalone (5 $\alpha$ -pregnan-3 $\alpha$ -ol-11,20-dione);

15.7 (2) alprazolam;

15.8 (3) barbital;

15.9 (4) bromazepam;

15.10 (5) camazepam;

15.11 (6) carisoprodol;

15.12 (7) chloral betaine;

15.13 (8) chloral hydrate;

15.14 (9) chlordiazepoxide;

15.15 (10) clobazam;

15.16 (11) clonazepam;

15.17 (12) clorazepate;

15.18 (13) clotiazepam;

15.19 (14) cloxazolam;

15.20 (15) delorazepam;

15.21 (16) diazepam;

15.22 (17) dichloralphenazone;

15.23 (18) estazolam;

15.24 (19) ethchlorvynol;

15.25 (20) ethinamate;

15.26 (21) ethyl loflazepate;

15.27 (22) fludiazepam;

15.28 (23) flurazepam;

- 16.1 (24) fospropofol;
- 16.2 (25) halazepam;
- 16.3 (26) haloxazolam;
- 16.4 (27) ketazolam;
- 16.5 (28) lorazepam;
- 16.6 (29) lorazepam;
- 16.7 (30) lormetazepam mebutamate;
- 16.8 (31) medazepam;
- 16.9 (32) meprobamate;
- 16.10 (33) methohexital;
- 16.11 (34) methylphenobarbital;
- 16.12 (35) midazolam;
- 16.13 (36) nimetazepam;
- 16.14 (37) nitrazepam;
- 16.15 (38) nordiazepam;
- 16.16 (39) oxazepam;
- 16.17 (40) oxazolam;
- 16.18 (41) paraldehyde;
- 16.19 (42) petrichloral;
- 16.20 (43) phenobarbital;
- 16.21 (44) pinazepam;
- 16.22 (45) prazepam;
- 16.23 (46) quazepam;
- 16.24 (47) suvorexant;
- 16.25 (48) temazepam;
- 16.26 (49) tetrazepam;
- 16.27 (50) triazolam;



17.1 (51) zaleplon;

17.2 (52) zolpidem;

17.3 (53) zopiclone.

17.4 (d) Any material, compound, mixture, or preparation which contains any quantity of the  
17.5 following substance including its salts, isomers, and salts of such isomers, whenever the  
17.6 existence of such salts, isomers, and salts of isomers is possible: fenfluramine.

17.7 (e) Stimulants. Unless specifically excepted or unless listed in another schedule, any  
17.8 material, compound, mixture, or preparation which contains any quantity of the following  
17.9 substances having a stimulant effect on the central nervous system, including its salts,  
17.10 isomers, and salts of isomers:

17.11 (1) cathine (norpseudoephedrine);

17.12 (2) diethylpropion;

17.13 (3) fencamfamine;

17.14 (4) fenproporex;

17.15 (5) mazindol;

17.16 (6) mefenorex;

17.17 (7) modafinil;

17.18 (8) pemoline (including organometallic complexes and chelates thereof);

17.19 (9) phentermine;

17.20 (10) pipradol;

17.21 (11) sibutramine;

17.22 (12) SPA (1-dimethylamino-1,2-diphenylethane).

17.23 (f) lorcaserin.